A
Andrea Gansz
Publications - 3
Citations - 208
Andrea Gansz is an academic researcher. The author has contributed to research in topics: Blood pressure & Ambulatory blood pressure. The author has an hindex of 3, co-authored 3 publications receiving 196 citations.
Papers
More filters
Journal ArticleDOI
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
Stephan Lüders,Joachim Schrader,Jürgen Berger,Thomas Unger,Walter Zidek,Michael Böhm,M. Middeke,Wolfgang Motz,Cornelia Lübcke,Andrea Gansz,Ludmer Brokamp,Roland E. Schmieder,Peter Trenkwalder,Herrmann Haller,P. Dominiak +14 more
TL;DR: Treatment of patients with high-normal office blood pressure with the angiotensin-converting enzyme inhibitor ramipril was well tolerated, and significantly reduced the risk of progression to manifest hypertension.
Journal ArticleDOI
Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2).
Peter Bramlage,Claudia Zemmrich,Andrea Gansz,Claus-Dieter Sturm,Rolf Fimmers,Jennifer Nadal,Roland E. Schmieder,Joachim Schrader,Stephan Lüders +8 more
TL;DR: Patients of Caucasian ethnicity with moderate essential hypertension uncontrolled on candesartan experienced a further drop in BP using olmesartan and amlodipine, and this was a prospective, single‐arm, phase IV study.
Journal ArticleDOI
Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
Claudia Zemmrich,Stephan Lüders,Andrea Gansz,Claus-Dieter Sturm,Rolf Fimmers,Jennifer Nadal,Roland E. Schmieder,Joachim Schrader,Peter Bramlage +8 more
TL;DR: Patients with uncontrolled moderate arterial hypertension being treated using candesartan monotherapy achieve a further reduction of BP when switched directly to a fixed‐dose combination of olmesartan 40 mg/amlodipine 10 mg.